Introduction
============

*Salmonella typhimurium* is associated with 1 million human deaths annually ([@B26]). It is the most important serotype of *Salmonella* that is transmitted from animals to humans, causing a marked threat to public health ([@B26]). Rabbits are an important source of meat and demand is increasing because of its nutritional and dietary properties ([@B20]; [@B12]). *S. typhimurium* is a common serovar causing abortion or systemic infection in rabbits at different stages, especially before and during weaning ([@B8]). Infection is mainly controlled using antimicrobials. Danofloxacin, the third generation of fluoroquinolones, is applied solely for veterinary use and displays excellent antimicrobial activity against both gram-negative and gram-positive bacteria ([@B29]). However, because of the development of resistance in bacteria, its efficacy is decreasing. It is generally considered that inappropriate use of antibacterials is the main reason for resistance development ([@B24]). Thus, to preserve the effectiveness of danofloxacin, the dose regimen should be optimized to maximize the therapeutic effect and minimize the emergence of resistance ([@B22]). A rational antibacterial dose regimen should be based on a good understanding of the pharmacokinetic and pharmacodynamic (PK/PD) relationship that bridges the gap between the PKs of an antibacterial in the target animal species and the PDs on the target bacteria species ([@B3]; [@B25]; [@B32]). The *ex vivo* PK/PD model of danofloxacin has been studied for several pathogens such as *Escherichia coli*, *Mannheimia haemolytica*, and *Staphylococcus aureus* in calves, sheep, goats, camels, chickens, and turkeys ([@B1],[@B2]; [@B29]; [@B19]; [@B28]). *In vivo* PK/PD modeling was also conducted in chickens against *Mycoplasma gallisepticum* ([@B36]). However, neither *ex vivo* nor *in vivo* PK/PD modeling of danofloxacin against *S. typhimurium* has been established.

Bacterial diseases may cause different bacterial burdens in different organs. However, PD evaluation in PK/PD modeling usually focuses on bacterial reduction in just one organ. Whether bacterial reduction in one organ can represent the efficacy of the drug in the host is unknown. Some studies reported diverse antibacterial actions in different organs after drug administration ([@B18]; [@B30]). The phenomenon indicated that the PK/PD surrogate value of an antimicrobial for the same effect might not be identical using bacterial reduction in different organs as PD endpoints.

Thus, in the present study, *in vivo* PK/PD modeling of danofloxacin against *S. typhimurium* was developed using the reductions of the bacterial burden in the blood, liver, spleen, and lung as the PD endpoints. The PK/PD indexes that best correlated with efficacy, and its corresponding magnitude, were determined.

Materials and Methods {#s1}
=====================

Organisms, Chemicals, and Animals
---------------------------------

The virulent *S. typhimurium* strain, HJ0310J was kindly supplied by Professor Da-Xing Peng (College of Veterinary Medicine, Yangzhou University, Yangzhou, Jiangsu Province, China). Danofloxacin mesylate (98%) was purchased from Yuanye Biotechnology, Co. Ltd. (Shanghai, China). The culture medium used in this experiment was purchased from Hope Biol-Technology, Co. Ltd. (Qingdao, China). One hundred and fifteen *S. typhimurium*-free New Zealand rabbits aged 5--6 weeks and weighing 0.8--1.2 kg were used in this study. Animals were housed in a clean environment for 1 week before the study, with free access to antibiotic-free feed and water. All the protocols were carried out in accordance with the guidelines of American Association for Accreditation of Laboratory Animal Care, Institute of Laboratory Animal Research, Commission on Life Sciences. The study was approved by the Animal Experiments Ethics Committee at Yangzhou University, with permission number SYXK(Su) IACUC 2017-0044.

*In Vitro* Pharmacodynamics Study
---------------------------------

The minimum inhibitory concentration (MIC) of danofloxacin against *S. typhimurium* and the standard organism *Salmonella enterica* subsp. *enterica* (ex Kauffmann and Edwards) Le Minor and Popoff serovar Typhimurium (ATCC 14028), cultivated in Mueller-Hinton (MH) broth, was evaluated using the micro-dilution method, according to the Clinical and Laboratory Standards Institute ([@B10]). The MIC in rabbit serum was also determined using the micro-dilution method according to a previous report ([@B37]). The minimum bactericidal concentration (MBC) in artificial medium and in rabbit serum was measured according to a previous report ([@B21]). Briefly, a 100-μL aliquot of suspensions from the MIC procedure were diluted and dropped onto MH agar plates. The bacteria were counted after incubation at 37°C for 48 h. The lowest concentration of danofloxacin that killed 99.9% of the bacteria was defined as the MBC. The mutant prevention concentration (MPC) was determined according to a previous report ([@B15]). The organism was cultured in MH broth for 24 h at 37°C, centrifuged at 3000 × *g* for 10 min, and re-suspended in MH broth to yield a concentration of ∼10^10^ colony forming units (cfu)/mL (confirmed through serial dilution and plating of 100 μL samples on MH agar). Then, ∼10^10^ cfu of microorganisms was spread on MH agar including serial concentrations of danofloxacin (1--32 × the MIC) and then incubated at 37°C for 96 h. The MPC was the lowest concentration that inhibited bacterial growth ([@B6]). The *in vitro* time kill curves of danofloxacin against *S. typhimurium* were determined at concentrations of 0, 0.5, 1, 2, 4, 8× the MIC, with an initial inoculum of ∼10^6^ cfu/mL. All experiments were performed in triplicate.

*Salmonella typhimurium* Infection Model
----------------------------------------

*Salmonella typhimurium* is a major cause of systemic infection in rabbits. Thus, an *S. typhimurium* infection model was used in this study. Briefly, strain HJ0310J was grown in broth overnight, and then centrifuged and re-suspended in commercially available saline. Animals were divided into four groups, five rabbits per group, and injected with 0.5 mL of saline containing 0, 10^7^, 10^8^, and 10^9^ cfu/mL of bacteria through the ear marginal vein. The same amounts of bacteria were injected 12 h later. Twelve hours after the last bacterial injection, the clinical symptoms, anatomy, and pathological changes were monitored. And then, animals were sacrificed by a lethal intravenous injection of beuthanasia (0.3 mL/kg) after anesthesia with ketamine- Xylazine. Bacterial loads in the blood, liver, spleen, and lung were estimated via dilution of tissue homogenates and plating onto Salmonella Shigella agar. The colonies were counted after incubation at 37°C for 24 h. The limit of detection was 2 × 10^3^ cfu/mL or 2 × 10^3^ cfu/g. The mortality rate was monitored until 84 h after the last bacterial inoculation using another four groups of animals (five rabbits per group).

Pharmacokinetics of Danofloxacin in the Infected Rabbits
--------------------------------------------------------

Thirty infected rabbits were divided into three groups randomly and treated with a single dose of 1, 10, or 30 mg/kg body weight (b.w.) danofloxacin via gavage. An aliquot of 0.5 mL of blood was collected from ear vein at 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, and 24 h post-drug administration. Serum was obtained through centrifuging the samples for 10 min at 3000 × *g*. High performance liquid chromatography with a fluorescence detector was used to determine the danofloxacin concentrations in serum, as described previously, with some modifications ([@B14]; [@B16]). Briefly, a 1-mL aliquot of trichloromethane was added to 200 μL of serum sample, vortexed for 5 min, and centrifuged at 12000 × *g* for 10 min. The supernatant was transferred, and the residue was re-extracted. The extracts were combined and evaporated to dryness under a gentle stream of nitrogen at 40°C. The residue was dissolved in 200 μL mobile phase containing phosphate buffer and acetonitrile (83:17, V/V, pH 3). Isocratic elution was used. The excitation and detection wavelengths were 280 and 450 nm, respectively. Good sensitivity and chromatographic behavior was achieved under this condition (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**). The recovery rate was 95.43--105.2%, and the coefficients of variation of inter-assay and intra-assay precision were lower than 10%. The limit of quantification (LOQ) was 0.02 μg/mL and the limit of determination (LOD) was 0.01 μg/mL. The pharmacokinetic data for danofloxacin were analyzed using the non-compartmental method in the WinNonlin software version 6.1 (Pharsight, St. Louis, MO, United States).

Effectiveness of Danofloxacin in the Infection Model
----------------------------------------------------

To evaluate the *in vivo* effectiveness of danofloxacin, infected rabbits were treated via gavage once daily for 3 successive days with 0.85% NaCl (control) or 1, 2.5, 5, 7.5, 10, 15, 20, and 30 mg/kg b.w. of danofloxacin (five animals per group). Treatment started at 12 h post-infection. At 24 h after the last dose, the animals were euthanized, and then their blood, livers, lungs, and spleens were sampled sterilely. The samples were homogenized and diluted with 0.85% NaCl. The bacterial loading in each organ was determined via plating dilutions onto Salmonella Shigella agar and counting the colonies after incubation at 37°C for 24 h.

Pharmacokinetics and Pharmacodynamics Analysis
----------------------------------------------

Fluoroquinolones such as danofloxacin are concentration-dependent drugs and the surrogate marker area under the concentration-time curve from 0 to 24 h/minimum inhibitory concentration (AUC~24\ h~/MIC) ratio is the best PK/PD parameter. Therefore, as a surrogate marker of danofloxacin's effectiveness, the AUC~24\ h~/MIC ratio was determined according to the *in vitro* MIC values and the PK parameters derived from three danofloxacin administrations via gavage. The effectiveness of danofloxacin was expressed as the bacterial reduction after treatment compared with that before treatment in each organ. The *in vivo* PK/PD relationships of danofloxacin in each organ were simulated using a sigmoid E~max~ model in the WinNonlin software (version 6.1; Pharsight) using the following equation:
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Where, E~0~ is the change in log~10~ cfu/mL or log~10~ cfu/g in the control sample (absence of danofloxacin). E~max~ is the difference in effect between the greatest amount of growth (as seen for the growth control, E~0~) and the greatest amount of killing. C~e~ is the AUC~24\ h~/MIC in the effect compartment. EC~50~ is the AUC~24\ h~/MIC value producing a 50% reduction in bacterial counts, and N is the Hill coefficient that describes the steepness of the AUC~24\ h~/MIC-effect curve ([@B7]).

Statistical Analysis
--------------------

The pharmacokinetic parameters of danofloxacin were presented as the mean ± SD. They were computed with the WinNonlin software (version 6.1; Pharsight). The same software was used for curve fitting to determine the relationship between the AUC~24\ h~/MIC ratios and the efficacy of danofloxacin. The GraphPad Prism software was used for time kill curve fitting. Other data were analyzed using SPSS (v.20) (SPSS Incorporated, Chicago, IL, United States). *P* \< 0.05 was regarded as statistically significant.

Results
=======

*In Vitro* Pharmacodynamics
---------------------------

The MIC and MBC of danofloxacin against *S. typhimurium* HJ0310J in MH broth were 0.03 and 0.06 μg/mL, while the corresponding values in rabbit serum were twice as high, at 0.06 and 0.12 μg/mL; respectively. The MPC in medium was eight times higher than the MIC, with a value of 0.25 μg/mL. The time-killing curve showed that with increasing amounts of the drug, the antibacterial effect was enhanced. Maximal killing was observed at 2× the MIC of danofloxacin (**Figure [1](#F1){ref-type="fig"}**).

![Time-killing curves of danofloxacin against *Salmonella typhimurium* in Mueller-Hinton (MH) broth with concentrations of danoflocaxin between 0 and 8× the minimum inhibitory concentration (MIC).](fphar-09-00391-g001){#F1}

*S. typhimurium* Infection Model
--------------------------------

Neither clinical signs nor anatomopathological lesions were observed in the control animals. The bacteriological assay was also negative in the control rabbits. Clinical symptoms, such as depression, decreased feeding, diarrhea, and fever, were observed in the other three infected groups. The symptoms became worse as the bacterial inoculation increased. After dissection, the bowel, spleen, and gallbladder were swollen, and there were bleeding spots in the duodenum. The survival curve of rabbits receiving 0, 0.5 × 10^7^, 0.5 × 10^8^, and 0.5 × 10^9^ cfu of *S. typhimurium* are shown in **Figure [2](#F2){ref-type="fig"}**. The corresponding survival rates of the four groups were 100, 80, 80, and 0% respectively. The bacterial loads in the blood, liver, spleen, and lung at 12 h after the last inoculation of ∼0.5 × 10^8^ cfu *S. typhimurium* HJ0310J were 6.51 ± 0.32, 6.56 ± 0.26, 7.73 ± 0.18, and 7.32 ± 0.32 log~10~ cfu/g, respectively. As a result, a inoculate of ∼0.5 × 10^8^ cfu was chosen for the infection model.

![The survival rate of rabbits 84 h after the last bacterial inoculation.](fphar-09-00391-g002){#F2}

Pharmacokinetics of Danofloxacin in Infected Rabbits
----------------------------------------------------

The PK profiles of danofloxacin and the main PK parameters are presented in **Figure [3](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**. The time of peak serum concentration (T~max~), elimination half-life (T~1/2β~), and clearance divided by bioavailability (CL~β~/F) for the three different doses showed little difference. However, the maximum serum concentration (C~max~) (0.18, 1.80, and 3.49 μg/mL) and AUC~24\ h~ (1.55, 11.70, and 28.10 μg h/mL) of the three doses increased in a concentration-dependent manner. A significant correlation between dose and C~max~ or AUC~24\ h~ was observed, with r^2^ values equal to 0.9592 and 0.9935, respectively. Thus, the AUC~24\ h~ of 2.5, 5, 7.5, 15, and 20 mg/kg b.w. doses could be deduced according to a linear relationship.

![Serum drug concentration-time profile of danofloxacin after oral administration at 1, 10, or 30 mg/kg body weight (b.w.) in *S. typhimurium* infected rabbits (*n* = 10/time point).](fphar-09-00391-g003){#F3}

###### 

Pharmacokinetic parameters of danofloxacin in serum following oral administration to *Salmonella typhimurium-*infected rabbits (*n* = 10/group).

  Parameter    1 mg/kg Mean ± *SD*   10 mg/kg Mean ± *SD*   30 mg/kg Mean ± *SD*
  ------------ --------------------- ---------------------- ----------------------
  C~max~       0.18 ± 0.04           1.80 ± 0.98            3.49 ± 0.91
  T~max~       1.60 ± 0.55           1.80 ± 1.30            1.40 ± 0.55
  T~1/2β~      15.30 ± 6.09          14.01 ± 9.34           11.38 ± 3.16
  AUC~24\ h~   1.55 ± 0.39           11.70 ± 4.47           28.10 ± 3.27
  CL~β~/F      0.45 ± 0.11           0.76 ± 0.30            0.84 ± 0.09
  Vz/F         9.36 ± 3.79           14.67 ± 10.00          13.65 ± 3.57
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*In Vivo* Pharmacokinetic and Pharmacodynamic Profiles of Danofloxacin
----------------------------------------------------------------------

The AUC~24\ h~/MIC ratios for doses of 0, 1, 2.5, 5, 7.5, 10, 15, 20, and 30 mg/kg were 0, 76.42, 119.60, 191.56, 263.54, 335.50, 479.44, 623.38, and 911.24, respectively. The profiles of the sigmoid E~max~ model describing the relationship between AUC~24\ h~/MIC and antibacterial effectiveness in each organ are presented in **Figure [4](#F4){ref-type="fig"}**. The surrogate AUC~24\ h~/MIC correlated well with effectiveness in each organ, with r^2^ values of 0.8971, 0.9186, 0.9581, and 0.8708 for blood, liver, spleen, and lung, respectively. The AUC~24\ h~/MIC value for the bactericidal effect in the blood, liver, spleen, and lung were 121.30, 354.28, 216.64, and 228.66, respectively (**Table [2](#T2){ref-type="table"}**). The slopes were 1.86, 2.47, 1.90, and 1.26 for the blood, liver, spleen, and lung, respectively. Thus, the *in vivo* effectiveness of danofloxacin against *S. typhimurium* in different organs varied.

![Sigmoid E~max~ relationships between danofloxacin's antibacterial effect in the blood, liver, spleen, and lung \[E, Log~10~ colony forming units (cfu)/mL or Log~10~ cfu/g\] and the *in vivo* area under the concentration-time curve from 0 to 24 h (AUC~24\ h~)/minimum inhibitory concentration (MIC) ratio in rabbits.](fphar-09-00391-g004){#F4}

###### 

Pharmacodynamic analysis of danofloxacin in infected rabbits targeting the blood, liver, spleen, and lung.

  Parameter (units)                               Blood    Liver    Spleen   Lung
  ----------------------------------------------- -------- -------- -------- --------
  E~max~ (Log10 cfu/mL)                           3.98     3.1      4.41     4.74
  E~0~ (Log~10~ cfu/mL)                           0.00     0.00     0.00     0.01
  EC~50~                                          66.54    89.84    145.66   148.18
  AUC~24\ h~/MIC for a 3 Log10 cfu/mL reduction   121.30   354.28   216.64   228.66
  Slope (N)                                       1.86     2.47     1.90     1.26
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/MIC: area under the concentration-time curve from 0 to 24 h/minimum inhibitory concentration ratio.

Discussion
==========

Fluoroquinolones are critical important antibiotics for human and animal health, to preserve the effectiveness of this kind of drugs, PK/PD modeling, especially *in vivo* PK/PD modeling, should be investigated to design a rational dosage ([@B11]; [@B33]; [@B4]). In the present study, *in vivo* PK/PD modeling of danofloxacin against *S. typhimurium* in rabbits was conducted and a series of interesting findings emerged.

The MIC and MBC for danofloxacin against *S. typhimurium* in rabbit serum were twice those in artificial broth, which could be explained by the protein binding ratio of danofloxacin in serum ([@B27]) and the differences of matrix. In accordance with previous reports, in which the MPC was eight times higher than the MIC ([@B23]), the ratio of MPC/MIC in this study was 8, indicating that the mutant selection window is wide. The *in vitro* time-killing curve of danofloxacin showed concentration dependence against *S. typhimurium*, which was similar to a previous publication ([@B21]).

This is the first report of danofloxacin pharmacokinetics in *S. typhimurium*-infected rabbits after oral administration. The CL/F of danofloxacin for three doses, ranging from 0.45 to 0.84 L/h/kg, showed little difference compared with a previous report, where the CL was 0.76 L/h/kg after intravenous injection of 6 mg/kg danofloxacin in healthy rabbits ([@B13]). However, the T~1/2β~ values in this study (15.30, 14.01, 11.38 h for 1, 10, 30 mg/kg b.w.) were much longer than those in healthy rabbits (4.88, 6.70, and 8.2 h for intravenous, intramuscular, and subcutaneous administration, respectively) ([@B13]). The longer T~1/2β~ in sick rabbits might reflect injury to their liver and kidneys, which agreed with the results of a previous publication ([@B34]). The results showed that *S. typhimurium* infection affects the elimination half-life of danofloxacin in rabbits and may further affect the PK/PD modeling results. The dose proportionality of danofloxacin pharmacokinetics in the range of 1 mg/kg to 30 mg/kg was described in the *S. typhimurium*-infected rabbits. The dose and AUC~24\ h~ or C~max~ showed significant correlations, which was in accordance with a previous report ([@B36]).

To the best of our knowledge, this is the first report of *in vivo* PK/PD modeling of danofloxacin against *S. typhimurium*. Targeting the bacterial burden in different organs, the PK/PD surrogate AUC~24\ h~/MIC showed a significant correlation with the *in vivo* antibacterial effects of danofloxacin against *S. typhimurium*, with an r^2^ value greater than 0.8708. However, the value of the PK/PD parameter, AUC~24\ h~/MIC, to attain a bactericidal effect, was different in each organ. It was reported that the concentration of danofloxacin in the lung was many times higher than that in plasma ([@B35]; [@B36]) and the V~z~ (ranging from 9.36 to 13.65 L/kg) in this study, indicating that danofloxacin can accumulate in tissues such as the lung, spleen, and liver. The AUC~24\ h~/MIC value for the bactericidal effect in the spleen and lung were almost twice those in the blood (216.64, 228.66, and 121.30 for the spleen, lung, and blood, respectively). One explanation could be that the initial bacterial loading in the spleen and lung was 10 times higher than that in the blood. It was reported previously that the initial bacterial loading seriously affects the PK/PD parameter values to attain a certain efficacy ([@B17]). However, the AUC~24\ h~/MIC value for the bactericidal effect in the liver (354.28) was higher than that in spleen and lung, and almost three times that in the blood. In addition, the initial bacterial load in the liver was the same as that in blood. The infection in this study was a severe model of sepsis based on a high load inoculation by the intravenous route. In addition, it was reported that the clearance of bacteria reflected the cooperation of antimicrobial and immune responses in the host ([@B5]). The spleen and liver play an important function (as filters of bacteria from the bloodstream) in the clearance of bacteria during bloodstream infection. The host defense mechanisms, especially hepatic clearance, contribute greatly to containing bacteremia ([@B9]). Thus, the AUC~24\ h~/MIC value for the bactericidal effect in the liver was much higher than that in blood and other organs. Similar results were reported in previous publications, where the bactericidal action of clofazimine against *M. tuberculosis* in the spleen was much stronger than that in the lung ([@B30]); meanwhile, the re-isolation rate of bacteria from the liver was much higher than that from spleen after the administration of a series of doses of enrofloxacin in *E. coli*-infected poultry ([@B18]).

To date, many reports focusing on the PK/PD relationship of fluoroquinolones have been published. Toutain reported that an AUC~24\ h~/MIC of 125 for fluoroquinolones was usually used as a threshold for ideal therapeutic outcome against gram-negative microbes ([@B31]). The PK/PD results in this study for the bacterial burden in the blood was similar to this threshold. Similarly, the AUC~24\ h~/MIC value for danofloxacin was close to 125 when deduced from *in vivo* PK/PD modeling. For example, the value of AUC~24\ h~/MIC for 3 Log~10~cfu/mL reduction was 97.98 h in chicken against *M. gallisepticum* ([@B36]). However, the value of AUC~24\ h~/MIC of danofloxacin was lower than 125 when deduced from *ex vivo* PK/PD modeling. For example, the AUC~24\ h~/MIC value was 6.73 in turkeys against *E. coli* ([@B19]); 33.5 h in calves against *Mannheimia haemolytica* ([@B29]); and 21.2 h in camels against *E. coli* ([@B1]). This phenomenon was also reported for other drugs, such as valnemulin ([@B33]). The possible reasons were elaborated in our previous study ([@B33]). These results further confirmed that *in vivo* PK/PD modeling has great advantages compared with *ex vivo* PK/PD modeling, and is more suitable to determine antibacterial efficiency predictors. However, the PK/PD parameter for bactericidal activity in this study targeted at the bacterial burden in the liver, spleen, and lung were much higher than 125, taking into consideration the immune response of animals during the first days of infection. According to our results, for systemic infection of bacteria, to explore and develop PK/PD model exactly, data from this kind of animal experiment, specifically bacterial loading reduction in different organs as PD endpoints, should be considered. The knowledge gained in this kind of study is important for the validation of PK/PD models and is critical to predict clinical efficacy and rational dosage recommendation. This study had some limitations. First, only one bacterium was evaluated; to confirm our findings, other bacteria in different backgrounds and from different species should be studied. Second, because of a lack of MIC data, we could not recommend the rational dose of danofloxacin against *S. typhimurium*. Further research is essential to determine the rational usage of danofloxacin.

Conclusion
==========

*In vivo* PK/PD modeling of danofloxacin against *S. typhimurium* in rabbits using bacterial loading in four organs (blood, liver, spleen, and lung) as PD endpoints was conducted. The AUC~24\ h~/MIC correlated well with the *in vivo* antibacterial effectiveness in the different organs, illustrating that the selection of the organ for PD determination had little effect on best PK/PD parameter determination. The AUC~24\ h~/MIC ratios for bactericidal effect were 121.30, 354.28, 216.64, and 228.66 in blood, liver, spleen, and lung, respectively, indicating that the selection of target organ for PD determination is critical for parameter magnitude calculation in antimicrobial PK/PD modeling, and in addition, would affect a rational dosage optimization process.
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Chromatograms of blank rabbit serum **(A)** and blank rabbit serum spiked at the level of 0.02 g/mL **(B)**.
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